Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Asimadoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asimadoline SCHEMBL2473545 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1CYP2D6 | |
| Asimadoline SCHEMBL155020 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1CYP2D6 | |
| Asimadoline SCHEMBL7721982 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1CYP2D6 | |
| Asimadoline SCHEMBL8717354 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1CYP2D6 | |
| Asimadoline SCHEMBL6923822 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1CYP2D6 | |
| Asimadoline SCHEMBL26923202 | 0.99 | OPRK1 (0.98) | OPRK1OPRM1OPRD1CYP2D6 | |
| Asimadoline SCHEMBL1179586 | 0.99 | OPRK1 (0.98) | OPRK1OPRM1OPRD1CYP2D6 | |
| Asimadoline SCHEMBL8011656 | 0.99 | OPRK1 (0.98) | OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL8720266 | 0.94 | OPRK1 (0.89) | OPRK1OPRM1OPRD1CYP2D6 | |
| SCHEMBL9015325 | 0.94 | OPRK1 (0.89) | OPRK1OPRM1OPRD1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2022-04-28 | — | — | US | disclosed |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-08-10 | — | — | US | disclosed |
| WO-2014210436-A2 | KAPPA OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS (US) | 2014-12-31 | — | — | WO | disclosed |
| EP-1572640-B1 | ASIMADOLINE DERIVATIVES COMPRISING COVALENTLY BONDED ACIDS | TIOGA PHARMACEUTICALS INC (US) | 2012-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885OPRM1 814/4885OPRD1 1577/4885 |
| US-20220125781-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885OPRM1 814/4885OPRD1 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.